The acquisition of Asklepios BioPharmaceutical (AskBio), while not a bargain, is a great move into the really hot topic of gene therapy. Based on the leading vector platform currently and pushed by numerous venture capital (VC) financing rounds, AskBio had built a broad and diversified R&D pipeline with three candidates in phase 1/2 trials. We see this as a major step towards better backward integration.
